



Press Enquiries:

GE Healthcare, International
Shaun Wootton
+44 (0) 1494 49 8068
shaun.wootton@ge.com

Saneron CCEL Therapeutics Inc.
Nicole Kuzmin-Nichols
+1 813 977 7664
nkn@saneron-ccel.com

GE Healthcare, Americas
Jean Leu
+1 732 457 8082
jean.leu@ge.com

PRESS RELEASE

GE HEALTHCARE AND SANERON ANNOUNCE RESEARCH COLLABORATION FOR UMBILICAL CORD BLOOD PROCESSING

CHALFONT ST. GILES, UK AND TAMPA, FL, NOVEMBER 21, 2005 – GE Healthcare, a unit of General Electric Company (NYSE: GE), and Saneron announced today a R&D agreement to optimize GE Healthcare's Ficoll-Paque™ for isolating stem cells from umbilical cord blood. The companies expect the new Ficoll-Paque to be manufactured under GMP standards. This cell population contains stem cells with the potential to be used to treat more than 80 malignant, genetic and acquired diseases, such as leukemia, lymphoma, sickle cell anemia, thalassemia and immunodeficiency.

“Umbilical cord blood is playing an increasingly important role in the use of cell therapy to successfully treat human disease,” said Nigel Darby, vice president of research and development, Protein Separations at GE Healthcare. “Saneron and GE Healthcare are working together to provide a solution for a sterile density medium manufactured under GMP conditions to meet the growing need for processing umbilical cord blood so that it may be used in cell therapy,”

Ficoll-Paque, a sterile density medium, has been used for 30 years to isolate high yields of mononuclear cells from peripheral blood and bone marrow. However, the cell composition in peripheral blood and bone marrow is significantly different from umbilical cord blood. Therefore,

a specialized version of Ficoll-Paque is necessary to optimally process stem cells from umbilical cord blood.

“Saneron has developed a proprietary processing technique to isolate a heterogeneous population of cells from umbilical cord blood that have shown promising results in preclinical studies of stroke, myocardial infarction, spinal cord injury, and ALS (Lou Gehrig’s disease). GE Healthcare’s cell separation media provides exceptional gradient separation of cells. This new version of Ficoll-Paque will be very valuable to Saneron in completing proof of principle studies required prior to the initiation of clinical trials,” said Dr. Cyndy Davis Sanberg, vice president of research, Saneron. “This is an important milestone in Saneron’s cord blood stem cell processing.”

The new Ficoll-Paque is being developed at GE’s Global Research Center in Niskayuna, NY, and tested at Saneron’s facilities at the University of South Florida’s research park. GE Healthcare will commercialize the final product. Financial terms were not disclosed.

ABOUT GE HEALTHCARE

GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring and life support systems, disease research, drug discovery, and biopharmaceutical manufacturing technologies is helping physicians detect disease earlier and tailor personalized treatments for their patients. GE Healthcare offers a broad range of products and services that are improving productivity in healthcare and enhancing patient care by enabling healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions.

Headquartered in the United Kingdom, GE Healthcare is a \$15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

ABOUT SANERON

Saneron is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Cryo-Cell International, Inc., Saneron is committed to providing readily available, non-controversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.